Oruka Therapeutics, Inc.
ORKA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $75 | $1 | $4 | $14 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13 | $6 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $88 | $7 | $10 | $19 |
| Operating Income | -$88 | -$7 | -$10 | -$19 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $2 | -$0 | $0 |
| Pre-Tax Income | -$84 | -$5 | -$10 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$84 | -$5 | -$10 | -$19 |
| % Margin | – | – | – | – |
| EPS | -4.99 | -4.44 | -8.27 | -16.68 |
| % Growth | -12.4% | 46.3% | 50.4% | – |
| EPS Diluted | -4.99 | -4.44 | -8.27 | -16.68 |
| Weighted Avg Shares Out | 17 | 14 | 14 | 14 |
| Weighted Avg Shares Out Dil | 17 | 14 | 14 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $2 | $1 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$82 | -$5 | -$10 | -$19 |
| % Margin | – | – | – | – |